Shares of Globus Medical (GMED) plummeted 19.94% in after-hours trading on Thursday following the release of the company's disappointing first-quarter 2025 financial results and reduced earnings outlook. The medical device maker's performance fell short of analyst expectations, raising concerns about its growth trajectory.

Globus Medical reported adjusted earnings per share (EPS) of $0.68 for Q1, missing the analyst consensus estimate of $0.74 by 8.11%. This represents a 5.56% decrease compared to the $0.72 per share reported in the same period last year. The company's quarterly sales also disappointed, coming in at $598.12 million, 4.44% below the analyst consensus estimate of $625.90 million and marking a 1.41% decrease from the $606.67 million recorded in the previous year's quarter.

Adding to investor concerns, Globus Medical cut its full-year 2025 adjusted EPS outlook to a range of $3.00 to $3.30, down from the previous guidance of $3.10 to $3.40. The company cited softer deal closures, temporary integration-related supply-chain disruptions, and the timing of international distributor orders as factors impacting its recent performance. Despite the earnings setback, Globus Medical reaffirmed its full-year 2025 revenue guidance in the range of $2.80 billion to $2.90 billion. As the medical device industry continues to face challenges, investors will be closely monitoring Globus Medical's strategies to address this underperformance and regain market confidence.